CMPX insider filings
Compass Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-02. Screen CMPX transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings by 1 insider — 22,500 shares, $21,250 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 20,000 shares @ $0.92 ($18,400) by Lerner Neil, filed 2026-10-02.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Lerner Neil — Chief Accounting Officer | 2 | 2 legs · 22,500 sh · $21,250 | — | — |
Recent insider filings — Compass Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Lerner Neil — Chief Accounting Officer | Purchase (P): 20,000 @ $0.92 | EDGAR |
| 2026-09-25 | 4 | Lerner Neil — Chief Accounting Officer | Purchase (P): 2,500 @ $1.14 | EDGAR |
| 2026-04-30 | 4/A | Anderman Jonathan — General Counsel | Purchase (P): 25,000 @ $1.89 | EDGAR |
| 2026-04-30 | 4/A | Lerner Neil — Chief Accounting Officer | Purchase (P): 15,000 @ $1.89 | EDGAR |
| 2026-04-29 | 4 | Anderman Jonathan — General Counsel | Grant/award (A): 25,000 @ $1.89 | EDGAR |
| 2026-04-29 | 4 | Lerner Neil — Chief Accounting Officer | Grant/award (A): 15,000 @ $1.89 | EDGAR |
| 2026-02-10 | 4 | Schuetz Thomas J. — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 36,687 @ $6.52 | EDGAR |
| 2026-01-12 | 4 | Schuetz Thomas J. — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 46,777 @ $5.35 | EDGAR |
| 2026-01-05 | 4 | Shin Barry — CFO | Grant/award (A): 125,000 @ $5.17 · Grant/award (A): 670,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Sirard Cynthia — Chief Medical Officer | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Prasad Arjun — Chief Commercial Officer | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Boylan James P — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Ferneau Philip — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Anderman Jonathan — General Counsel | Grant/award (A): 150,000 @ $5.17 · Grant/award (A): 720,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Schuetz Thomas J. — CEO, Director | Grant/award (A): 250,000 @ $5.17 · Grant/award (A): 2,000,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Lerner Neil — Chief Accounting Officer | Grant/award (A): 62,500 @ $5.17 · Grant/award (A): 435,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Chiniara Ellen — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | GORDON CARL L — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | GRAY MARY ANN — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | LINDAHL RICHARD S — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Schuetz Thomas J. — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 44,025 @ $4.83 | EDGAR |
| 2025-05-27 | 4 | Schuetz Thomas J. — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 10,000 @ $2.11 | EDGAR |
| 2025-04-11 | 4 | GORDON CARL L — Director, 10% owner | Sale (S): 3,571,428 @ $1.59 | EDGAR |
| 2025-04-11 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VI LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Sale (S): 3,571,428 @ $1.59 | EDGAR |
| 2025-04-08 | 4 | Anderman Jonathan — Gen Counsel & Corporate Sec | Purchase (P): 20,000 @ $1.54 | EDGAR |
| 2025-04-08 | 4 | Lerner Neil — CHIEF ACCOUNTING OFFICER | Purchase (P): 20,000 @ $1.42 | EDGAR |
| 2025-02-13 | 4 | Shin Barry — CFO | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | Ferneau Philip — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | Anderman Jonathan — Sr VP, Gen Counsel & Corp Sec | Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | Boylan James P — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | Schuetz Thomas J. — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 1,500,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | Lerner Neil — SVP, CAO | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | Chiniara Ellen — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | GORDON CARL L — Director, 10% owner | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | GRAY MARY ANN — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-02-13 | 4 | LINDAHL RICHARD S — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Schuetz Thomas J. — CEO, Director | Tax withholding (F): 41,687 @ $3.50 | EDGAR |
| 2025-01-13 | 4 | Schuetz Thomas J. — CEO, Director | Tax withholding (F): 58,054 @ $1.86 | EDGAR |
| 2024-12-10 | 4 | Shin Barry — CFO | Grant/award (A): 400,000 @ $1.65 · Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Anderman Jonathan — Sr VP, Gen Counsel & Corp Sec | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Boylan James P — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Ferneau Philip — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Chiniara Ellen — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | GORDON CARL L — Director, 10% owner | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | GRAY MARY ANN — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | LINDAHL RICHARD S — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Bisker-Leib Vered — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 49,198 @ $1.45 | EDGAR |
| 2024-02-09 | 4 | Schuetz Thomas J. — PRESIDENT, Director | Tax withholding (F): 44,782 @ $1.45 | EDGAR |
| 2024-01-10 | 4 | Bisker-Leib Vered — Chief Executive Officer, Director | Grant/award (A): 1,753,125 @ $1.93 · Grant/award (A): 1,753,125 (derivative) @ $0 | EDGAR |
| 2024-01-10 | 4 | Schuetz Thomas J. — President of R&D, Director | Grant/award (A): 637,500 @ $1.93 · Grant/award (A): 637,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Compass Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-06 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CMPX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →